These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26668204)

  • 1. Clinical and Economic Impact of Formulary Conversion From Inhaled Flolan to Inhaled Veletri for Refractory Hypoxemia in Critically Ill Patients.
    Torbic H; Szumita PM; Anger KE; Nuccio P; Lagambina S; Weinhouse G
    Ann Pharmacother; 2016 Feb; 50(2):106-12. PubMed ID: 26668204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome.
    Hawn JM; Bauer SR; Wanek MR; Li M; Wang X; Duggal A; Torbic H
    Ann Pharmacother; 2020 May; 54(5):434-441. PubMed ID: 31729256
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness, safety, and Economic Comparison of Two Inhaled Epoprostentol Products (Flolan and Veletri) in Cardiothoracic Surgery Patients.
    Hawn JM; Wanek M; Bauer SR; Ammar MA; Insler S; Adi A; Torbic H
    Ann Pharmacother; 2018 Oct; 52(10):956-964. PubMed ID: 29749260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.
    Torbic H; Szumita PM; Anger KE; Nuccio P; LaGambina S; Weinhouse G
    J Crit Care; 2013 Oct; 28(5):844-8. PubMed ID: 23683572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS.
    Ammar MA; Bauer SR; Bass SN; Sasidhar M; Mullin R; Lam SW
    Ann Pharmacother; 2015 Oct; 49(10):1105-12. PubMed ID: 26187741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled epoprostenol improves oxygenation in severe hypoxemia.
    Tabrizi MB; Schinco MA; Tepas JJ; Hwang J; Spiwak E; Kerwin AJ
    J Trauma Acute Care Surg; 2012 Aug; 73(2):503-6. PubMed ID: 23019678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19.
    Sonti R; Pike CW; Cobb N
    J Intensive Care Med; 2021 Mar; 36(3):327-333. PubMed ID: 33234007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure.
    Meyer J; Theilmeier G; Van Aken H; Bone HG; Busse H; Waurick R; Hinder F; Booke M
    Anesth Analg; 1998 Apr; 86(4):753-8. PubMed ID: 9539597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity of Hypoxemia and Other Factors That Influence the Response to Aerosolized Prostacyclin in ARDS.
    Kallet RH; Burns G; Zhuo H; Ho K; Phillips JS; Pangilinan LP; Yip V; Gomez A; Lipnick MS
    Respir Care; 2017 Aug; 62(8):1014-1022. PubMed ID: 28559468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled epoprostenol to support the severely hypoxemic patient with acute respiratory distress syndrome.
    Arumpanayil A
    Dimens Crit Care Nurs; 2013; 32(5):229-36. PubMed ID: 23933641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of inhaled prostacyclin in treating acute respiratory distress syndrome.
    Searcy RJ; Morales JR; Ferreira JA; Johnson DW
    Ther Adv Respir Dis; 2015 Dec; 9(6):302-12. PubMed ID: 26294418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients.
    Enomoto TM; Treggiari MM; Yanez ND; Merkel MJ
    Respir Care; 2019 Jul; 64(7):743-751. PubMed ID: 30967439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: A quality improvement project.
    Davis SL; Crow JR; Fan JR; Mattare K; Whitman G; Brower RG; Rowden A; Pustavoitau A
    Am J Health Syst Pharm; 2019 Sep; 76(18):1413-1419. PubMed ID: 31372630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of inhaled epoprostenol in patients with H1N1 influenza-associated acute respiratory distress syndrome: a case series.
    McMillen JC; Burke CF; Dhingra A; Dudney TM; Faircloth BE
    Ann Pharmacother; 2011 May; 45(5):e26. PubMed ID: 21540407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled Epoprostenol Through Noninvasive Routes of Ventilator Support Systems.
    Ammar MA; Sasidhar M; Lam SW
    Ann Pharmacother; 2018 Dec; 52(12):1173-1181. PubMed ID: 29890848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery.
    McGinn K; Reichert M
    Ann Pharmacother; 2016 Jan; 50(1):22-6. PubMed ID: 26438636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults.
    Buckley MS; Agarwal SK; Garcia-Orr R; Saggar R; MacLaren R
    J Intensive Care Med; 2021 Apr; 36(4):466-476. PubMed ID: 32133901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective review of implementation of an inhaled epoprostenol protocol in the emergency department.
    Toomey D; O'Brien M; Hayes BD; Wilcox S
    Am J Emerg Med; 2022 Aug; 58():210-214. PubMed ID: 35709539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19.
    Poonam PBH; Koscik R; Nguyen T; Rikhi S; Lin HM
    PLoS One; 2022; 17(6):e0270646. PubMed ID: 35759496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019.
    DeGrado JR; Szumita PM; Schuler BR; Dube KM; Lenox J; Kim EY; Weinhouse GL; Massaro AF
    Crit Care Explor; 2020 Oct; 2(10):e0259. PubMed ID: 33134949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.